Market Closed -
Nyse
04:00:02 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
129.3
USD
|
-0.59%
|
|
+1.35%
|
+18.59%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
231,557
|
206,957
|
193,588
|
281,302
|
276,259
|
327,467
|
-
|
-
|
Enterprise Value (EV)
1 |
247,453
|
230,686
|
218,594
|
298,801
|
304,221
|
346,378
|
335,069
|
321,148
|
P/E ratio
|
23.9
x
|
29.4
x
|
14.9
x
|
19.4
x
|
779
x
|
16.7
x
|
14.5
x
|
13.3
x
|
Yield
|
2.48%
|
3.03%
|
3.44%
|
2.52%
|
2.72%
|
2.4%
|
2.53%
|
2.69%
|
Capitalization / Revenue
|
4.94
x
|
4.31
x
|
3.97
x
|
4.75
x
|
4.6
x
|
5.11
x
|
4.77
x
|
4.51
x
|
EV / Revenue
|
5.28
x
|
4.81
x
|
4.49
x
|
5.04
x
|
5.06
x
|
5.4
x
|
4.88
x
|
4.42
x
|
EV / EBITDA
|
12.6
x
|
11.2
x
|
10.5
x
|
11.3
x
|
30.2
x
|
11.8
x
|
10.1
x
|
9.09
x
|
EV / FCF
|
24.8
x
|
41.4
x
|
25.2
x
|
20.3
x
|
33.3
x
|
18.7
x
|
14.4
x
|
12.7
x
|
FCF Yield
|
4.03%
|
2.41%
|
3.97%
|
4.92%
|
3.01%
|
5.33%
|
6.96%
|
7.85%
|
Price to Book
|
9
x
|
8.18
x
|
5.07
x
|
6.12
x
|
7.34
x
|
6.6
x
|
5.16
x
|
4.18
x
|
Nbr of stocks (in thousands)
|
2,545,984
|
2,530,034
|
2,525,944
|
2,535,396
|
2,534,023
|
2,532,806
|
-
|
-
|
Reference price
2 |
90.95
|
81.80
|
76.64
|
111.0
|
109.0
|
129.3
|
129.3
|
129.3
|
Announcement Date
|
2/5/20
|
2/4/21
|
2/3/22
|
2/2/23
|
2/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
46,840
|
47,994
|
48,704
|
59,283
|
60,115
|
64,106
|
68,596
|
72,647
|
EBITDA
1 |
19,572
|
20,570
|
20,910
|
26,431
|
10,083
|
29,287
|
33,103
|
35,310
|
EBIT
1 |
15,920
|
16,945
|
17,696
|
22,522
|
6,211
|
26,198
|
29,653
|
32,230
|
Operating Margin
|
33.99%
|
35.31%
|
36.33%
|
37.99%
|
10.33%
|
40.87%
|
43.23%
|
44.36%
|
Earnings before Tax (EBT)
1 |
11,464
|
8,791
|
13,879
|
16,444
|
1,889
|
23,931
|
25,057
|
28,393
|
Net income
1 |
9,843
|
7,067
|
13,049
|
14,519
|
365
|
19,507
|
22,271
|
24,752
|
Net margin
|
21.01%
|
14.72%
|
26.79%
|
24.49%
|
0.61%
|
30.43%
|
32.47%
|
34.07%
|
EPS
2 |
3.810
|
2.780
|
5.140
|
5.710
|
0.1400
|
7.744
|
8.922
|
9.752
|
Free Cash Flow
1 |
9,967
|
5,569
|
8,674
|
14,707
|
9,143
|
18,476
|
23,321
|
25,211
|
FCF margin
|
21.28%
|
11.6%
|
17.81%
|
24.81%
|
15.21%
|
28.82%
|
34%
|
34.7%
|
FCF Conversion (EBITDA)
|
50.92%
|
27.07%
|
41.48%
|
55.64%
|
90.68%
|
63.09%
|
70.45%
|
71.4%
|
FCF Conversion (Net income)
|
101.26%
|
78.8%
|
66.47%
|
101.29%
|
2,504.93%
|
94.72%
|
104.71%
|
101.86%
|
Dividend per Share
2 |
2.260
|
2.480
|
2.640
|
2.800
|
2.960
|
3.101
|
3.272
|
3.477
|
Announcement Date
|
2/5/20
|
2/4/21
|
2/3/22
|
2/2/23
|
2/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
13,521
|
15,901
|
14,593
|
14,959
|
13,830
|
14,487
|
15,035
|
15,962
|
14,630
|
15,775
|
15,822
|
16,665
|
15,958
|
16,565
|
17,490
|
EBITDA
1 |
5,670
|
7,568
|
6,649
|
6,516
|
5,698
|
5,402
|
-3,485
|
7,538
|
665
|
7,367
|
7,364
|
8,236
|
7,613
|
-
|
-
|
EBIT
1 |
4,835
|
6,448
|
5,711
|
5,557
|
4,806
|
4,411
|
-4,388
|
6,524
|
-299
|
6,383
|
6,504
|
7,018
|
6,279
|
-
|
-
|
Operating Margin
|
35.76%
|
40.55%
|
39.14%
|
37.15%
|
34.75%
|
30.45%
|
-29.19%
|
40.87%
|
-2.04%
|
40.46%
|
41.11%
|
42.11%
|
39.35%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
3,583
|
3,513
|
3,650
|
-5,335
|
5,620
|
-2,046
|
5,670
|
6,044
|
6,461
|
5,750
|
-
|
-
|
Net income
1 |
3,758
|
4,310
|
3,944
|
3,248
|
3,017
|
2,821
|
-5,975
|
4,745
|
-1,226
|
4,762
|
4,955
|
5,443
|
4,814
|
-
|
-
|
Net margin
|
27.79%
|
27.11%
|
27.03%
|
21.71%
|
21.81%
|
19.47%
|
-39.74%
|
29.73%
|
-8.38%
|
30.19%
|
31.32%
|
32.66%
|
30.17%
|
-
|
-
|
EPS
2 |
1.480
|
1.700
|
1.550
|
1.280
|
1.180
|
1.110
|
-2.350
|
1.860
|
-0.4800
|
1.870
|
1.938
|
2.124
|
1.944
|
-
|
-
|
Dividend per Share
2 |
0.6900
|
0.6900
|
0.6900
|
0.6900
|
0.7300
|
0.7300
|
0.7300
|
0.7300
|
0.7700
|
0.7700
|
0.7700
|
0.7700
|
0.7700
|
-
|
-
|
Announcement Date
|
2/3/22
|
4/28/22
|
7/28/22
|
10/27/22
|
2/2/23
|
4/27/23
|
8/1/23
|
10/26/23
|
2/1/24
|
4/25/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
15,896
|
23,729
|
25,006
|
17,499
|
27,962
|
18,912
|
7,602
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
6,318
|
Leverage (Debt/EBITDA)
|
0.8122
x
|
1.154
x
|
1.196
x
|
0.6621
x
|
2.773
x
|
0.6457
x
|
0.2296
x
|
-
|
Free Cash Flow
1 |
9,967
|
5,569
|
8,674
|
14,707
|
9,143
|
18,477
|
23,321
|
25,211
|
ROE (net income / shareholders' equity)
|
50.9%
|
58.9%
|
41.1%
|
45.2%
|
9.18%
|
48.7%
|
44.3%
|
39.8%
|
ROA (Net income/ Total Assets)
|
11.8%
|
17.1%
|
13.2%
|
17.7%
|
3.56%
|
18.3%
|
19.3%
|
19.5%
|
Assets
1 |
83,517
|
41,231
|
98,641
|
82,070
|
10,266
|
106,746
|
115,433
|
127,198
|
Book Value Per Share
2 |
10.10
|
10.00
|
15.10
|
18.10
|
14.80
|
19.60
|
25.00
|
30.90
|
Cash Flow per Share
2 |
5.210
|
4.040
|
5.170
|
7.510
|
5.110
|
11.10
|
11.50
|
12.20
|
Capex
1 |
3,473
|
4,684
|
4,448
|
4,388
|
3,863
|
3,752
|
3,928
|
3,900
|
Capex / Sales
|
7.41%
|
9.76%
|
9.13%
|
7.4%
|
6.43%
|
5.85%
|
5.73%
|
5.37%
|
Announcement Date
|
2/5/20
|
2/4/21
|
2/3/22
|
2/2/23
|
2/1/24
|
-
|
-
|
-
|
Last Close Price
129.3
USD Average target price
141.6
USD Spread / Average Target +9.55% Consensus |
1st Jan change
|
Capi.
|
---|
| +18.59% | 327B | | +29.98% | 682B | | +30.34% | 586B | | -3.52% | 364B | | +4.07% | 285B | | +16.21% | 240B | | +9.66% | 209B | | -6.83% | 203B | | +7.09% | 165B | | -1.22% | 161B |
Other Pharmaceuticals
|